Exenatide: Potential Type 2 Diabetes Therapy
Targets beta cells
- Restored first-phase insulin
Three AMIGOs met primary endpoints
- Reductions in A1C of ~1 percent regardless of background therapy
- Approximately 40 percent achieve A1C </= 7 percent
- Accompanied by weight loss
- Generally well tolerated
Durable effect through 52 weeks
- Reductions in A1C sustained
- Progressive weight loss